Innate Pharma S.A.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 35.48 | -100% | -15.14 | -100% |
| P/S |
|
3.87 | 3.31 | 17% |
|
|
| P/BV |
|
4.28 | 3.11 | 37.27% |
|
|
| P/FCF |
|
0 | 14.05 | -100% |
|
|
| Ev/Ebitda |
|
-9.96 | 11.99 | -183.09% |
|
|
| Ev/S |
|
3.33 | 2.76 | 20.93% |
|
|
| Ev/FCF |
|
-4.96 | 12.58 | -139.4% |
|
|
| E/P |
|
0 | 1.47 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-33.45 | 25.06 | -233.46% | -78.04 | -57.14% |
| ROE |
|
-16.19 | 12.29 | -231.69% |
|
|
| ROA |
|
-4.56 | 5.97 | -176.44% |
|
|
| ROIC |
|
0 | 15.56 | -100% |
|
|
| ROS |
|
-14.66 | 12.34 | -218.83% |
|
|
| ROCE |
|
-47.62 | 14.8 | -421.68% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-2.06 | 6.19 | -133.21% | -2.16 | -4.74% |
| Nеt Debt/Ebitda |
|
1.6 | -3.89 | -141.03% |
|
|
| Debt/Ratio |
|
0.2143 | 0.2205 | -2.83% |
|
|
| Debt/Equity |
|
2.55 | 1.01 | 152.75% |
|
|
| Debt/Net Income |
|
-4.69 | 16.9 | -127.78% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 1.55 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 1.38 | -100% | ||
| DSI |
|
0 | 0.7718 | -100% |
|
|
| Average dividend growth |
|
0 | -260.86 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 2.72 | -100% |
|
|
| Average percentage for payments |
|
0 | 168.02 | -100% |
|
|
| Difference from average difference in sector |
|
-1.55 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
1/10
|
5.69 | 33.42 | -82.97% | ||
| Growth impulse Ebitda in 5 years |
|
1.16 | 26.07 | -95.55% | ||
| Growth impulse Net Income in 5 years |
|
-56.72 | 27.45 | -306.63% | ||
| Growth impulse FCF in 5 years |
|
35.59 | 11.59 | 207.08% | ||
| Growth impulse EPS in 5 years |
|
-64.11 | 79.86 | -180.28% |
IP Score
2.91/10
